Gothenburg, Sweden

Bengt R Andersson


Average Co-Inventor Count = 7.6

ph-index = 6

Forward Citations = 164(Granted Patents)


Location History:

  • Molndal, SE (1986)
  • Lindome, SE (1993 - 1994)
  • 413 11 Goteborg, SE (1995)
  • Goteborg, SE (1995 - 1997)
  • Gothenburg, SE (1994 - 1998)

Company Filing History:


Years Active: 1986-1998

Loading Chart...
11 patents (USPTO):Explore Patents

Title: **Bengt R Andersson: Innovating Pharmacological Solutions**

Introduction

Bengt R Andersson, an influential inventor based in Gothenburg, Sweden, has made significant contributions to the field of pharmacology. With a portfolio of 11 patents, his work reflects a deep commitment to innovation, particularly in developing compounds that have therapeutic applications in treating central nervous system disorders.

Latest Patents

Among Andersson's latest patents are groundbreaking compounds such as 2-aminoindans, which serve as selective dopamine D3 ligands. Another notable patent involves centrally acting 6,7,8,9-tetrahydro-3H-benz(e) indole heterocyclics. The compounds outlined in these patents have various structural formulas, including modifications that exhibit potential for treating complexities associated with the central nervous system. Their innovative chemical properties highlight a considerable advancement in pharmacological research.

Career Highlights

Throughout his career, Bengt R Andersson has been associated with renowned companies, including The Upjohn Company and Pharmacia & Upjohn Company. His time at these institutions allowed him to further refine his inventive skills and advance the development of new medicinal compounds. The depth of his experience is evident in his patents, demonstrating both creativity and scientific rigor.

Collaborations

Andersson has collaborated with esteemed colleagues, including Per A Carlsson and Hakan V Wikstrom. These partnerships have played an essential role in his innovative process, leading to the development of new pharmaceutical products that address vital health issues.

Conclusion

Bengt R Andersson's commitment to innovation in pharmacology is unmistakable. With significant achievements illustrating his capability to create compounds aimed at enhancing the treatment of central nervous system disorders, he remains a respected figure in the scientific community. His patents continue to pave the way for further advancements in medical therapies, marking a profound impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…